139 related articles for article (PubMed ID: 22237576)
1. Response to PHARMAC on Access to new medicines in New Zealand compared to Australia.
Milne R; Wonder M
N Z Med J; 2011 Dec; 124(1347):91-3. PubMed ID: 22237576
[No Abstract] [Full Text] [Related]
2. Access to new medicines in New Zealand compared to Australia.
Wonder M; Milne R
N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
[TBL] [Abstract][Full Text] [Related]
3. Do pharmaceutical score cards give us the answers we seek?
Moodie P; Metcalfe S; Poynton M
N Z Med J; 2011 Nov; 124(1346):69-74. PubMed ID: 22143855
[TBL] [Abstract][Full Text] [Related]
4. Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.
Taylor C; Wonder M
Aust Health Rev; 2015 Sep; 39(4):455-461. PubMed ID: 25751688
[TBL] [Abstract][Full Text] [Related]
5. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
6. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
Gleeson D; Lopert R; Reid P
Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
[TBL] [Abstract][Full Text] [Related]
7. Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003.
Wonder MJ; Neville AM; Parsons R
Value Health; 2006; 9(4):205-12. PubMed ID: 16903989
[TBL] [Abstract][Full Text] [Related]
8. Author reply: exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.
Taylor CB; Wonder M
Aust Health Rev; 2016 Feb; 40(1):120. PubMed ID: 26254890
[No Abstract] [Full Text] [Related]
9. Comparing the reimbursement of new medicines between Australia and New Zealand.
Ragupathy R; Babar ZU
Aust Health Rev; 2016 Feb; 40(1):118-119. PubMed ID: 26189014
[No Abstract] [Full Text] [Related]
10. The subsidy of pharmaceuticals in Australia: processes and challenges.
Sansom L
Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399
[TBL] [Abstract][Full Text] [Related]
11. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
12. Prescription drugs are the biggest bargain in health care, and all Americans should have access to them.
Holmer AF
Md Med; 2003; 4(2):48-9. PubMed ID: 12847830
[No Abstract] [Full Text] [Related]
13. Drug card setback highlights need for cost relief.
Gundling RL
Healthc Financ Manage; 2003 Apr; 57(4):50-4. PubMed ID: 12735187
[TBL] [Abstract][Full Text] [Related]
14. Patient access to pharmaceuticals: an international comparison.
Cohen J; Faden L; Predaris S; Young B
Eur J Health Econ; 2007 Sep; 8(3):253-66. PubMed ID: 17279403
[TBL] [Abstract][Full Text] [Related]
15. Unexpected "donut hole" raises concerns that patients will fail to fill needed prescriptions.
Howard-Ruben J
ONS News; 2006 Dec; 21(12):10-1. PubMed ID: 17193936
[No Abstract] [Full Text] [Related]
16. The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand.
Aaltonen K; Ragupathy R; Tordoff J; Reith D; Norris P
Value Health; 2010; 13(1):148-56. PubMed ID: 19744294
[TBL] [Abstract][Full Text] [Related]
17. An Rx for reform: a Medicare prescription drug benefit.
Rak J
Health Matrix Clevel; 2002; 12(2):449-505. PubMed ID: 12430363
[No Abstract] [Full Text] [Related]
18. Medication access and continuity under Medicare Part D.
Pollack DA
Am J Psychiatry; 2007 May; 164(5):700-1. PubMed ID: 17475724
[No Abstract] [Full Text] [Related]
19. Is there any evidence that the Trans Pacific Partnership Agreement will threaten access to affordable medicines and health equity in New Zealand?
Wonder M; Milne R
Health Policy; 2014 Jun; 116(2-3):234-5. PubMed ID: 24560197
[No Abstract] [Full Text] [Related]
20. The Health Impact Fund: incentives for improving access to medicines.
Banerjee A; Hollis A; Pogge T
Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
